Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology. The company develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis. The company is also developing a range of assays for tick-borne diseases, such as lyme disease, as well as for use in screening blood for the parasite babesia microti that causes babesiosis; and T-SPOT.CMV test that measures the strength of a patient's cellular response to CMV infection. Oxford Immunotec Global PLC markets its T-SPOT.TB test through a direct sales force in the United States, certain European countries, and Japan, as well as through distributors in other parts of the world. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OXFD
CUSIPN/A
Phone44-0-12-3544-2780
Debt
Debt-to-Equity Ratio0.38
Current Ratio5.60
Quick Ratio5.04
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$103.08 million
Price / Sales3.48
Cash FlowN/A
Price / CashN/A
Book Value$3.42 per share
Price / Book4.06
Profitability
EPS (Most Recent Fiscal Year)($1.36)
Net Income$-32,880,000.00
Net Margins-34.13%
Return on Equity-43.51%
Return on Assets-24.49%
Miscellaneous
Employees457
Outstanding Shares25,880,000
Oxford Immunotec Global (NASDAQ:OXFD) Frequently Asked Questions
What is Oxford Immunotec Global's stock symbol?
Oxford Immunotec Global trades on the NASDAQ under the ticker symbol "OXFD."
How were Oxford Immunotec Global's earnings last quarter?
Oxford Immunotec Global PLC (NASDAQ:OXFD) announced its quarterly earnings results on Tuesday, May, 1st. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.45) by $0.05. The business earned $21.37 million during the quarter, compared to analyst estimates of $20.96 million. Oxford Immunotec Global had a negative return on equity of 43.51% and a negative net margin of 34.13%. The firm's revenue was down .7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.36) EPS. View Oxford Immunotec Global's Earnings History.
When is Oxford Immunotec Global's next earnings date?
What price target have analysts set for OXFD?
4 analysts have issued 1-year target prices for Oxford Immunotec Global's shares. Their predictions range from $15.00 to $20.00. On average, they anticipate Oxford Immunotec Global's stock price to reach $18.25 in the next year. View Analyst Ratings for Oxford Immunotec Global.
Who are some of Oxford Immunotec Global's key competitors?
Some companies that are related to Oxford Immunotec Global include Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Lantheus (LNTH), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), Vermillion (VRML), ImmuCell (ICCC), Akers Biosciences (AKER), GeneNews (GNWSF), Arca Biopharma (ABIO), Achieve Life Sciences (ACHV) and Fluoropharma Medical (FPMI).
Who are Oxford Immunotec Global's key executives?
Oxford Immunotec Global's management team includes the folowing people:
- Dr. Peter Wrighton-Smith, CEO & Exec. Director (Age 44)
- Mr. Richard M. Altieri, CFO and Principal Financial & Accounting Officer (Age 58)
- Mr. Jeff R. Schroeder, Pres, Strategic Accounts (Age 57)
- Mr. Stefan C. Linn, Chief Operating Officer (Age 53)
- Ms. Karen C. Koski, Head of Strategy & Investor Relations
Has Oxford Immunotec Global been receiving favorable news coverage?
News headlines about OXFD stock have trended somewhat positive on Saturday, Accern reports. Accern ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Oxford Immunotec Global earned a news sentiment score of 0.13 on Accern's scale. They also assigned news articles about the company an impact score of 47.24 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are Oxford Immunotec Global's major shareholders?
Oxford Immunotec Global's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Redmile Group LLC (9.54%), BlackRock Inc. (4.49%), Wasatch Advisors Inc. (2.88%), First Light Asset Management LLC (2.42%), Cortina Asset Management LLC (1.98%) and Northern Trust Corp (1.00%). Company insiders that own Oxford Immunotec Global stock include Elizabeth M Keiley, Jeff R Schroeder, Peter Edwardson, Peter Wrighton-Smith and Richard A Sandberg. View Institutional Ownership Trends for Oxford Immunotec Global.
Which institutional investors are selling Oxford Immunotec Global stock?
OXFD stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Cortina Asset Management LLC, Tiverton Asset Management LLC, Millennium Management LLC, Neuburgh Advisers LLC, Flinton Capital Management LLC, C WorldWide Group Holding A S and Northern Trust Corp. Company insiders that have sold Oxford Immunotec Global company stock in the last year include Peter Edwardson, Peter Wrighton-Smith and Richard A Sandberg. View Insider Buying and Selling for Oxford Immunotec Global.
Which institutional investors are buying Oxford Immunotec Global stock?
OXFD stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Redmile Group LLC, BlackRock Inc., Spark Investment Management LLC, Birchview Capital LP, First Light Asset Management LLC, Trexquant Investment LP and Kornitzer Capital Management Inc. KS. View Insider Buying and Selling for Oxford Immunotec Global.
How do I buy shares of Oxford Immunotec Global?
Shares of OXFD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Oxford Immunotec Global's stock price today?
One share of OXFD stock can currently be purchased for approximately $13.87.
How big of a company is Oxford Immunotec Global?
Oxford Immunotec Global has a market capitalization of $364.41 million and generates $103.08 million in revenue each year. The company earns $-32,880,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. Oxford Immunotec Global employs 457 workers across the globe.
How can I contact Oxford Immunotec Global?
Oxford Immunotec Global's mailing address is 94C INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RZ. The company can be reached via phone at 44-0-12-3544-2780 or via email at [email protected]
MarketBeat Community Rating for Oxford Immunotec Global (OXFD)
MarketBeat's community ratings are surveys of what our community members think about Oxford Immunotec Global and other stocks. Vote "Outperform" if you believe OXFD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OXFD will underperform the S&P 500 over the long term. You may vote once every thirty days.
